Results 191 to 200 of about 194,150 (247)
GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate
Reproductive BioMedicine Online, 2013 The availability of gonadotrophin-releasing hormone (GnRH) antagonists for ovarian stimulation protocols has generated many meta-analyses comparing it to GnRH agonist long protocols. These meta-analyses have yielded conflicting results for pregnancy rate,
Raoul Orvieto, Pasquale Patrizio
exaly +2 more sources
Gynecological Endocrinology, 2009 BACKGROUND: The aim of this study was to evaluate the response to treatment in a group of patients undergoing IVF and randomised to receive GnRH-antagonist or the GnRH-agonist.
Paolo Trerotoli +2 more
exaly +2 more sources
Fertility and Sterility, 2012 To evaluate whether serum antimüllerian hormone (AMH) levels are affected in early maturing girls, and whether pituitary suppression by long-acting GnRH agonist (GnRH-a) affects ...
Casper P Hagen +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Best Practice & Research Clinical Obstetrics & Gynaecology, 2007
Gonadotropin-releasing hormone (GnRH) agonists were introduced in ovarian stimulation for in-vitro fertilization to suppress the premature surge of luteinizing hormone (LH). Although agonist use is accompanied by a series of disadvantages, including hypoestrogenaemia, cyst formation, a requirement for a prolonged period of downregulation, and an ...
B C, Tarlatzis, E M, Kolibianakis
openaire +2 more sources
Gonadotropin-releasing hormone (GnRH) agonists were introduced in ovarian stimulation for in-vitro fertilization to suppress the premature surge of luteinizing hormone (LH). Although agonist use is accompanied by a series of disadvantages, including hypoestrogenaemia, cyst formation, a requirement for a prolonged period of downregulation, and an ...
B C, Tarlatzis, E M, Kolibianakis
openaire +2 more sources
Safety of GnRH agonists and antagonists
Expert Opinion on Drug Safety, 2004The widespread application of protocols using gonadotropin-releasing hormone (GnRH) agonists or antagonists in assisted reproduction treatment has led to an increasing number of pregnancies exposed to these drugs. This issue has raised scepticism as to the safety of these medications, concerning both pregnant women and their offspring.
Basil C, Tarlatzis, Helen, Bili
openaire +2 more sources
Clinical Obstetrics and Gynecology, 1989
The development of GnRH agonists has had a major impact on the practice of gynecology and reproductive endocrinology. The clinical usefulness of GnRH agonists will increase as modes of administration are improved and indications become better defined. GnRH agonists and, potentially, antagonists will provide a prompt, effective, and reversible method of
openaire +2 more sources
The development of GnRH agonists has had a major impact on the practice of gynecology and reproductive endocrinology. The clinical usefulness of GnRH agonists will increase as modes of administration are improved and indications become better defined. GnRH agonists and, potentially, antagonists will provide a prompt, effective, and reversible method of
openaire +2 more sources
Journal of Obstetric, Gynecologic & Neonatal Nursing, 1994
Gonadotropin-releasing hormone agonists are a relatively new class of drugs, which, when chronically administered, result in marked reductions in blood levels of testosterone and estrogen. These drugs include leuprolide acetate (Lupron); the first GnRH agonist to be approved in the United States, nafarelin acetate (Synarel); and goserelin acetate ...
openaire +2 more sources
Gonadotropin-releasing hormone agonists are a relatively new class of drugs, which, when chronically administered, result in marked reductions in blood levels of testosterone and estrogen. These drugs include leuprolide acetate (Lupron); the first GnRH agonist to be approved in the United States, nafarelin acetate (Synarel); and goserelin acetate ...
openaire +2 more sources
Drugs, 1988
Gonadotrophin-releasing hormone (GnRH) analogues offer a novel approach for the non-steroidal manipulation of the reproductive endocrine axis. GnRH agonists are now effectively employed in the management of precocious puberty, prostate and breast cancer, endometriosis, uterine leiomyoma, polycystic ovarian disease, and various other disorders ...
M, Filicori, C, Flamigni
openaire +2 more sources
Gonadotrophin-releasing hormone (GnRH) analogues offer a novel approach for the non-steroidal manipulation of the reproductive endocrine axis. GnRH agonists are now effectively employed in the management of precocious puberty, prostate and breast cancer, endometriosis, uterine leiomyoma, polycystic ovarian disease, and various other disorders ...
M, Filicori, C, Flamigni
openaire +2 more sources
GnRH-agonists in fertility preservation
Current Opinion in Endocrinology, Diabetes & Obesity, 2008Description of the recent progress in fertility preservation despite gonadotoxic chemotherapy, using gonadotropin-releasing hormone (GnRH)-agonists (GnRH-a).Most groups of investigators have found a beneficial effect of the administered GnRH-a on minimizing the chemotherapy-associated gonadotoxic effect, in both hematologic diseases, mainly Hodgkin ...
openaire +2 more sources
2020
In vitro fertilization, commonly referred to as IVF, is a procedure in which infertility of varied etiologies is overcome. The current standard of care requires ovaries to be sufficiently stimulated to allow the collection of many oocytes, which are then fertilized in the laboratory and eventually transferred to a receptive uterine cavity.
Megan Schneiderman, Michael H. Dahan
openaire +1 more source
In vitro fertilization, commonly referred to as IVF, is a procedure in which infertility of varied etiologies is overcome. The current standard of care requires ovaries to be sufficiently stimulated to allow the collection of many oocytes, which are then fertilized in the laboratory and eventually transferred to a receptive uterine cavity.
Megan Schneiderman, Michael H. Dahan
openaire +1 more source